ClinicalTrials.gg

Program

asedebart

Also written as “Lu AG13909” and “Asedebart”.

Its studies are mostly in Adrenal Hyperplasia, Congenital · Pituitary ACTH Hypersecretion, led by H. Lundbeck.

Furthest: phase 2, since Dec 20, 20223 company-led studies, 3 open or runningNext primary completion: Aug 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck33 open or runningphase 2since Dec 20, 2022Dec 20, 2022Aug 10, 2027phase 2 · NCT06471829

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2022First study: phase 2 study in Adrenal Hyperplasia, CongenitalFirst studyNCT05669950 · 42 planned · United States, Denmark, France and more
  2. Jun 18, 2024Phase 2 study in Pituitary ACTH HypersecretionNCT06471829 · 16 enrolled · United States, France, Georgia and more
  3. Sep 29, 2026Phase 2 study in Adrenal Hyperplasia, CongenitalNCT07859293 · 45 planned
  4. Oct 16, 2026Primary completion moved from 2026-09-15 to 2027-08-10Date moved laterphase 2 · +11 months · NCT06471829

Ahead

  1. Aug 10, 2027Primary completion: phase 2 study in Pituitary ACTH HypersecretionNCT06471829
  2. Jul 31, 2031Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNCT07859293

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07859293Adrenal Hyperplasia, Congenital2Not yet recruitingJul 31, 203145
NCT06471829Pituitary ACTH Hypersecretion · United States, France, Georgia and more2Active, not recruitingAug 10, 202716
NCT05669950Adrenal Hyperplasia, Congenital · United States, Denmark, France and more2RecruitingSep 30, 202642

How it is read

Names in the registry

  • “Lu AG13909”, 2 entries
  • “Asedebart”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.